Safety and Efficacy of Multi-Target TKI Combined with Nivolumab in Check-Point Inhibitor-Refractory Patients with Advanced NSCLC: a Prospective, Single-Arm, Two-Stage Study
BMC Cancer（2024）
Key words
NSCLC,Checkpoint inhibitor-refractory,Nivolumab,Anlotinib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined